# Libervant® (diazepam) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/diazepam

> The FDA approved Libervant® (diazepam), sponsored by Aquestive Therapeutics, Inc. (AQST), on February 14, 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Libervant® (diazepam) FDA approved?

Yes. The FDA approved Libervant® (diazepam), sponsored by Aquestive Therapeutics, Inc. (AQST), on February 14, 2025. SEC Form 10-Q: "On February 14, 2025, in a lawsuit brought by Neurelis, the owner of the FDA approved nasal spray Valtoco, against the FDA (Neurelis, Inc. v. Califf, for which the Company joined as a Defendant Intervenor) challenging the FDA's approval of Libervant for ARS patients aged between two and five years, the U.S. District for the District of Columbia issued a final appealable order entering a judgment in favor of Neurelis's motion for summary judgment and vacating the FDA's approval of Libervant." [Calendar and source filings](https://sec-api.dev/pdufa/diazepam)

Source: SEC Form 10-Q, accession 0001398733-26-000042, https://www.sec.gov/Archives/edgar/data/1398733/000139873326000042/aqst-20260630.htm (retrieved 2026-11-12). Last confirmed 2026-08-11. Cite: https://sec-api.dev/pdufa/diazepam#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Libervant® (diazepam) |
| Codes |  |
| Sponsor | Aquestive Therapeutics, Inc. (AQST) https://sec-api.dev/companies/aqst/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | orphan |

## Timeline

### Aug 2022: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-03-05, last confirmed 2025-03-05.
- Press release filed with the SEC (EX-99) (accession 0001628280-25-010422): "The FDA granted tentative approval in August 2022 for Libervant for treatment of ARS patients twelve years of age and older, with U.S. market access for Libervant for this age group of patients subject to the expiration of the existing orphan drug market exclusivity of a previously FDA approved nasal spray drug scheduled to expire in January 2027." https://www.sec.gov/Archives/edgar/data/1398733/000162828025010422/aqst-q424xex991earningsrel.htm

### April 29, 2024: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-03-05, last confirmed 2025-03-05.
- SEC Form 10-K (accession 0001628280-25-010506): "On April 29, 2024, we announced that the FDA approved U.S. market access for Libervant in ARS patients between two to five years of age." https://www.sec.gov/Archives/edgar/data/1398733/000162828025010506/aqst-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-010422): "Aquestive received FDA approval of Libervant for patients aged between two and five years in April of 2024." https://www.sec.gov/Archives/edgar/data/1398733/000162828025010422/aqst-q424xex991earningsrel.htm

### February 14, 2025: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-11-05, last confirmed 2026-08-11.
- SEC Form 10-Q (accession 0001398733-26-000042): "On February 14, 2025, in a lawsuit brought by Neurelis, the owner of the FDA approved nasal spray Valtoco, against the FDA (Neurelis, Inc. v. Califf, for which the Company joined as a Defendant Intervenor) challenging the FDA's approval of Libervant for ARS patients aged between two and five years, the U.S. District for the District of Columbia issued a final appealable order entering a judgment in favor of Neurelis's motion for summary judgment and vacating the FDA's approval of Libervant." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000042/aqst-20260630.htm
- SEC Form 10-Q (accession 0001398733-26-000030): "On February 14, 2025, in a lawsuit brought by Neurelis, the owner of the FDA approved nasal spray Valtoco, against the FDA (Neurelis, Inc. v. Califf, for which the Company joined as a Defendant Intervenor) challenging the FDA's approval of Libervant for ARS patients aged between two and five years, the U.S. District for the District of Columbia issued a final appealable order entering a judgment in favor of Neurelis's motion for summary judgment and vacating the FDA's approval of Libervant." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000030/aqst-20260331.htm
- SEC Form 10-K (accession 0001398733-26-000018): "On February 14, 2025, in a lawsuit brought by Neurelis, Inc. ("Neurelis"), the owner of the FDA approved nasal spray Valtoco, against the FDA (Neurelis, Inc. v. Califf, for which the Company joined as a Defendant Intervenor) challenging the FDA's approval of Libervant for ARS patients aged between two and five years, the U.S. District for the District of Columbia issued a final appealable order entering a judgment in favor of Neurelis's motion for summary judgment and vacating the FDA's approval of Libervant." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/aqst-20251231.htm
- SEC Form 10-Q (accession 0001398733-25-000028): "On February 14, 2025, in a lawsuit brought by Neurelis, Inc. ("Neurelis"), the owner of the FDA approved nasal spray Valtoco, against the FDA (Neurelis, Inc. v. Califf, for which the Company joined as a Defendant Intervenor) challenging the FDA's approval of Libervant for ARS patients aged between two and five years, the U.S. District for the District of Columbia issued a final appealable order entering a judgment in favor of Neurelis's motion for summary judgement and vacating the FDA's approval of Libervant." https://www.sec.gov/Archives/edgar/data/1398733/000139873325000028/aqst-20250930.htm

### Q2 2025: trial start

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2025-03-05, last confirmed 2025-03-05.
- Press release filed with the SEC (EX-99) (accession 0001628280-25-010422): "Plan to open the IND and initiate a Phase 2a study in Q2 2025 Libervant® (diazepam) Buccal Film for patients ages 2-5 years old (epilepsy)" https://www.sec.gov/Archives/edgar/data/1398733/000162828025010422/q42024supplementalearnin.htm

### Jan 2027: NDA/BLA submission

- Status: scheduled. Date confidence: month.
- First seen 2025-01-13, last confirmed 2025-01-13.
- Press release filed with the SEC (EX-99) (accession 0001628280-25-001229): "The Company plans to submit an NDA and launch Libervant for these epilepsy patients between 6 to 11 years of age, if approved by the FDA, upon the expiration of the existing orphan drug market exclusivity scheduled to expire in January 2027." https://www.sec.gov/Archives/edgar/data/1398733/000162828025001229/aqstbusinessupdate2025-f.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/diazepam.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Libervant® (diazepam) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/diazepam

```bibtex
@misc{secapidev_pdufa_diazepam_20261116,
  title        = {Libervant® (diazepam) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/diazepam}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_diazepam_20261116","title":"Libervant® (diazepam) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/diazepam","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
